kelifutinib

Kelifutinib (HEC88477) is a potent and selective small-molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3), developed by Guangdong Dongyangguang Pharmaceutical (HEC Pharm). It is specifically designed to target FLT3 mutations, such as internal tandem duplications (FLT3-ITD) and tyrosine kinase domain (FLT3-TKD) mutations, which are prevalent in approximately 30% of acute myeloid leukemia (AML) cases and are associated with a high risk of relapse and poor overall survival. By competitively binding to the ATP-binding site of the FLT3 receptor, kelifutinib inhibits downstream signaling pathways (including PI3K/Akt, MAPK/ERK, and STAT5), thereby inducing cell cycle arrest and apoptosis in leukemic cells. The drug is currently being evaluated in clinical trials for patients with relapsed or refractory AML.

Other names

kelifutinib